Annotation Detail

Information
Associated Genes
NRG1
Associated Variants
NRG1 EXPRESSION
NRG1 EXPRESSION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/813
Gene URL
https://civic.genome.wustl.edu/links/genes/2593
Variant URL
https://civic.genome.wustl.edu/links/variants/314
Rating
4
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Patritumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26137564
Drugs
Drug NameSensitivitySupported
PatritumabSensitivitytrue